Dovitinib

Target: This ligand targets FGFR, VEGFR, PDGFR, FLT3, KIT, and CSF1R receptor tyrosine kinases in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for FGFR, VEGFR, PDGFR, FLT3, KIT, and CSF1R receptor tyrosine kinases. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings FGFR into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Kinase-Targeted PROTAC Design: Dovitinib can serve as a kinase-binding ligand to recruit a target protein within a PROTAC construct. By coupling Dovitinib to an appropriate E3 ligase binder, researchers can test whether ternary complex formation drives ubiquitination and degradation, enabling selective removal of kinase function in cellular models.

• Multi-Kinase Degradation Studies: Because Dovitinib is known to engage multiple kinase targets, it is useful for probing how ligand promiscuity impacts PROTAC selectivity. Systematic PROTAC panel screening can identify which kinase(s) are preferentially degraded, helping refine structure–activity relationships and improve degradation specificity.

• Ternary Complex Optimization: Dovitinib-based PROTACs can be used to study how linker length, attachment position, and conformational constraints affect cooperative binding. Measuring binding kinetics and degradation potency can reveal whether efficient ternary complex stabilization correlates with robust target turnover.

• Pathway Dissection via Degradation: Dovitinib-derived PROTACs enable degradation-based interrogation of signaling pathways rather than inhibition alone. By comparing phenotypes from degradation versus kinase blockade, researchers can determine whether loss of the target protein produces distinct downstream effects, including altered phosphorylation states and transcriptional responses.

Dovitinib is a multikinase ligand scaffold suitable for kinase-directed PROTAC design, particularly when a degrader program requires a compact heteroaromatic target-binding ligand. The piperazine-containing region provides a practical vector for linker exploration while the kinase-recognition core should be preserved.

Structure: Dovitinib contains a fused heteroaromatic quinolinone/benzimidazole-like kinase-binding scaffold bearing an amino group, a fluorinated aromatic region, and an aryl N-methylpiperazine substituent. The structure includes multiple ring nitrogens, one lactam carbonyl, an aniline-type amino group, and a tertiary basic piperazine, giving the molecule both hydrogen-bonding capacity and a solvent-facing polar side-chain region.

Reactivity: For PROTAC construction, the N-methylpiperazine-containing aryl substituent is the most appropriate region to evaluate for linker installation, because it is more likely to tolerate extension than the fused heteroaromatic kinase-binding core. Alkyl, PEG, amide, carbamate, urea, or tertiary-amine-compatible linker designs can be considered for pairing with CRBN, VHL, IAP, or other E3 ligase ligands. The lactam carbonyl, amino-substituted heteroaryl core, and fluorinated aromatic binding elements should be preserved unless SAR data support modification.